Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 Article

Emu, Brinda, Fessel, Jeffrey, Schrader, Shannon et al. (2018). Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 . New England Journal of Medicine, 379(7), 645-654. 10.1056/NEJMoa1711460

Open Access International Collaboration

cited authors

  • Emu, Brinda; Fessel, Jeffrey; Schrader, Shannon; Kumar, Princy; Richmond, Gary; Win, Sandra; Weinheimer, Steven; Marsolais, Christian; Lewis, Stanley

sustainable development goals

authors

publication date

  • August 16, 2018

published in

keywords

  • ANTI-CD4 MONOCLONAL-ANTIBODY
  • ANTIRETROVIRAL THERAPY
  • CD4
  • DRUG-RESISTANCE
  • EFFICACY
  • ENFUVIRTIDE
  • General & Internal Medicine
  • INDIVIDUALS
  • INFECTION
  • Life Sciences & Biomedicine
  • Medicine, General & Internal
  • RECONSTITUTION INFLAMMATORY SYNDROME
  • RHESUS-MONKEYS
  • Science & Technology

Digital Object Identifier (DOI)

start page

  • 645

end page

  • 654

volume

  • 379

issue

  • 7